1. Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma
- Author
-
William J. Bruce, Aziz U. Khan, Michael W. Neumeister, Jessie L Koljonen, and Michael R. Romanelli
- Subjects
Oncology ,medicine.medical_specialty ,Skin Neoplasms ,business.industry ,medicine.medical_treatment ,Melanoma ,Immunotherapy ,medicine.disease ,Combined Modality Therapy ,Neoadjuvant Therapy ,Oncolytic virus ,Targeted therapy ,Clinical trial ,Chemotherapy, Adjuvant ,Internal medicine ,Cutaneous melanoma ,medicine ,Adjuvant therapy ,Humans ,Surgery ,business ,Adjuvant - Abstract
Adjuvant therapy plays an integral role in the treatment algorithm for stage III and stage IV cutaneous melanoma. Current ongoing clinical trials are exploring the effects of neoadjuvant therapeutics, specifically for the presurgical treatment of high-risk, borderline resectable disease. In both the adjuvant and neoadjuvant settings, the early chemotherapeutic and biochemical antitumor agents are making way to newer immune therapies, mutation-specific targeted therapies, and oncolytic vaccines that are transforming the treatment of malignant melanoma. The use of these systemic therapies in addition to surgical resection has been shown to increase both overall and progression-free survival.
- Published
- 2021